At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
PF-299804 (Dacomitinib)drug
Likely dose
PF-299804 (Dacomitinib) 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of PF299804, a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation
Grupo Español de Investigación en Neurooncología·interventional·Posted Jan 30, 2012·Updated Jul 6, 2021
In Brief
A Phase 2 clinical trial evaluating PF-299804 (Dacomitinib) for Glioblastoma and Brain Tumor, Recurrent. Completed, enrolled 49 participants across 12 sites.
Detailed Summary
This multicenter, 2-stage, open-label, phase II trial aims to assess the efficacy and safety of dacomitinib in adult patients with recurrent Glioblastoma (GBM) with EGFR gene amplification and/or EGFRvIII mutation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma, Brain Tumor, Recurrent
CountriesSpain
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartFeb 2012
Primary CompletionApr 2015
Study CompletionMar 2017
TodayJul 2026
First PostedJan 30, 2012
Enrollment StartFeb 1, 2012
Primary CompletionApr 1, 2015
Study CompletionMar 9, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 14.4 years ago
Interventions
PF-299804 (Dacomitinib)drug
Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.